Poor
Mostly Misaligned
Patient Risk:
Moderate
Summary
Most claims are either not supported by the provided LYRICA prescribing-information excerpts or introduce exercise/fitness-specific pharmacokinetic and dosing assertions that are not addressed in the label excerpts. Several additional details (e.g., specific creatinine clearance-based formula, forum-user worsening, sweating/endurance exercise effects, specific monitoring recommendations for “eGFR regularly” in certain groups) are not supported by the supplied label text and may conflict with label framing that emphasizes renal impairment and drug interactions rather than physical activity.
Category Scores
Accurate Statements
Pregabalin is eliminated largely by renal excretion (renal clearance/renal elimination).
Label: 2.1 ("eliminated primarily by renal excretion"), and 12.3 ("eliminated largely by renal excretion").
Unsupported Statements
Lyrica does not require routine dose adjustments specifically for fitness activities (weight training, cardio, general exercise) in patients with normal kidney function.
The provided label excerpts discuss dose adjustment for reduced renal function but do not address exercise/fitness activity as a dosing factor.
Exercise-induced changes such as temporary dehydration or altered blood flow do not significantly impact pregabalin pharmacokinetics in healthy individuals.
The provided label excerpts do not describe effects of dehydration, altered blood flow, or exercise on pregabalin pharmacokinetics.
Pregabalin prescribing information focuses dose adjustments on renal impairment, age, or drug interactions rather than physical activity levels.
The provided label excerpts specifically support renal adjustment; they do not substantiate claims about “age” or “drug interactions” being the focus for dosing decisions, nor do they mention physical activity levels.
When creatinine clearance is below 60 mL/min, pregabalin doses drop (example given: from 300–600 mg/day to 75–300 mg/day).
While the label excerpts reference creatinine clearance thresholds for maximum dosing in specific indications (e.g., for neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia), they do not provide a general dose-drop example across indications matching the numeric pairings and phrasing used here.
Heavy sweating or endurance exercise can mildly increase pregabalin levels due to reduced kidney perfusion.
The provided label excerpts do not describe exercise-induced sweating/endurance effects on pregabalin exposure or kidney perfusion.
A stated dosing adjustment formula for pregabalin is: Total daily dose = (creatinine clearance / 60) × standard dose.
The provided label excerpts do not provide this formula; they only state that dose should be adjusted based on renal function and reference tables (e.g., Table 2) without supplying a linear formula in the excerpt.
Gym-goers over 65 or on diuretics face higher risks and should test eGFR regularly.
The provided label excerpts do not state that diuretic use requires routine eGFR testing, nor do they include a gym/exercise-related risk statement or “over 65” monitoring instruction.
Dizziness is reported to worsen after cardio by some forum users.
The label excerpts contain controlled-trial incidence rates for dizziness, but do not mention forum reports or cardio-specific worsening timing.
Splitting pregabalin doses (e.g., morning/evening) or timing workouts before evening doses helps some patients reduce dizziness worsening post-cardio.
The provided label excerpts include general administration/tapering guidance and divided-dose instructions for certain seizure regimens, but do not support cardio timing, workout timing, or exercise-specific dizziness management strategies.
A recommendation is to start low if new to Lyrica and intense training, and to monitor for unsteadiness.
The label excerpts support starting low in certain contexts (e.g., respiratory depression co-prescribing) but do not include training/exercise context or a recommendation tied to intense training for unsteadiness monitoring.
No formal dose tweak is recommended unless kidney function is compromised.
The provided label excerpts clearly support renal dose adjustment; however, the claim that no other dose adjustment is recommended is broader than the supplied excerpts and is not directly supported by the provided text.
Patients with underlying renal issues may need baseline creatinine checks before starting Lyrica.
The provided label excerpts mention adjusting dose in adult patients with reduced renal function but do not specify baseline creatinine-check practice.
Increased pregabalin levels may potentially amplify side effects such as dizziness, fatigue, or sedation.
The label excerpts state dose-dependent adverse reactions, and that pregabalin may cause dizziness/somnolence, but they do not support the exercise-induced increased-level mechanism or that side effects will be amplified specifically by increased levels from exercise.
Heavy sweating or endurance exercise can mildly increase pregabalin levels due to reduced kidney perfusion.
Not addressed in supplied label excerpts.
Contradictions
Low
AI Statement
Pregabalin prescribing information focuses dose adjustments on renal impairment, age, or drug interactions rather than physical activity levels.
Label Reference
2.1 indicates renal adjustment based on reduced renal function; the provided excerpt set does not substantiate the assertion about age/drug interactions as the primary other factors nor does it address physical activity. (Not directly contradicted, but partially misstated emphasis.)
Important Omissions
Label-based contraindication for hypersensitivity to pregabalin/components (and related angioedema/hypersensitivity discontinuation) was not discussed in the fitness/exercise-focused claims.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Because multiple claims assert exercise/fitness-specific effects on pregabalin exposure and provide dosing/monitoring guidance tied to workouts rather than label-supported renal adjustment, there is a risk of misapplication (e.g., assuming no dose adjustment is needed beyond kidney function, or using workout timing/dose-splitting to manage label-defined dizziness/somnolence) despite the provided label emphasizing renal excretion and dose-dependent adverse reactions.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Mostly Misaligned
Primary Issue
Exercise/fitness-specific pharmacokinetic and dosing assertions (dehydration/blood flow/sweating effects, workout timing to reduce dizziness, linear creatinine clearance formula, and eGFR testing guidance for diuretics/age) are not supported by the provided prescribing information excerpts.
Suggested Improvement
Restrict claims to label-supported statements in the provided excerpts: pregabalin is eliminated primarily by renal excretion; dose adjust in adults with reduced renal function (via label tables); LYRICA can cause dizziness and somnolence; and taper gradually. Remove exercise-specific PK statements and forum/user-based assertions, and avoid providing non-labeled dosing formulas or monitoring instructions not present in the supplied label text.